Resources

Protecting and Licensing AI Inventions

• Slides

Facilitating Collaboration in the Life Sciences – Funding, Licensing, and International Collaboration

• Slides

Life Sciences Case Management: The Judicial Perspective

• Patent Case Management Judicial Guide, 3rd Edition

• FJC Patent Pilot Program Final Report

• FJC Patent Mediation Guide

• FJC Tutorials on Science and Technology

Protecting IP and Litigating into Uncertainty: Challenges from Sections 101 and 112 in the Life Sciences

• Slides
• Amgen Inc. v. Sanofi, Aventisub LLC, 987 F.3d 1080 (Fed. Cir. 2021)
• Juno Therapeutics, Inc. v. Kite Pharma., 10 F.4th 1330 (Fed. Cir. 2021)

• Materials from “The State of Patent Eligibility in America” Congressional Committee Hearings (June 4-6, 2019):

  The State of Patent Eligibility in America: Part I. (2019). Meeting | Hearings | United States Senate Committee on the Judiciary. Retrieved April 20, 2022, from https://www.judiciary.senate.gov/meetings/the-state-of-patent-eligibility-in-america-part-i.

  The State of Patent Eligibility in America: Part Ii. (2019). Meeting | Hearings | United States Senate Committee on the Judiciary. Retrieved April 20, 2022, from https://www.judiciary.senate.gov/meetings/the-state-of-patent-eligibility-in-america-part-ii.

  The State of Patent Eligibility in America: Part Iii. (2019). Meeting | Hearings | United States Senate Committee on the Judiciary. Retrieved April 20, 2022, from https://www.judiciary.senate.gov/meetings/the-state-of-patent-eligibility-in-america-part-iii.

• Various Materials from the United States Patent Trademark Office pertaining to section 101 subject matter eligibility:

  USPTO, & Hirshfeld, A., 86 Patent Eligibility Jurisprudence Study 776–780 (2021). Federal Register.

  USPTO, & Hirshfeld, A., 87 Deferred Subject Matter Eligibility Response Pilot Program 776–780 (2022). Federal Register.

  USPTO, & Iancu, A., 842019 Revised Patent Subject Matter Eligibility Guidance 50–57 (2019). Federal Register.

Carving Out Induced Infringement: Strategy for Skinny Labels

• Slides
• Carrier, Michael A., The US Court of Appeals for the Federal Circuit Reverses a Judgment that Upheld ‘Skinny Labels’ and Allowed a Generic To Launch on Uses Not Covered by a Patent (GlaxoSmithKline/Teva) (December 1, 2020). e-Competitions (No. 98366, Dec. 2020), Rutgers Law School Research Paper No. Forthcoming, Available at SSRN: https://ssrn.com/abstract=3740745
• Kas, D. (2021, February 9). Fed. Circ. Panel Walks Back $235M Skinny Label Ruling. Law360. Retrieved April 20, 2022, from https://www.law360.com/articles/1349886/fed-circ-panel-walks-back-235m-skinny-label-ruling.

Antitrust Considerations in Structuring Pharmaceutical Settlements and Deals

• AMG CAPITAL MANAGEMENT, LLC, ET AL. v. FEDERAL TRADE COMMISSION (SUPREME COURT OF THE UNITED STATES April 22, 2021).
• Ass’n for Accessible Meds. v. Bonta, 2:20-cv-01708-TLN-DB (E.D. Cal. Feb. 14, 2022)

• ASSOCIATION FOR ACCESSIBLE MEDICINES, v. ROB BONTA, in his official capacity as Attorney General of the State of California, (UNITED STATES DISTRICT COURT EASTERN DISTRICT OF CALIFORNIA December 8, 21AD).

• Executive Order. 14036 of Jul 9, 2021 
• Gallagher, M., Grannon, E., McDevitt, H., O’Shaughnessy, K., Acosta, A., Adam , K. C., & Wang, A. Y. (2021, October 12). United States: Pharmaceutical Antitrust. Global Competition Review. Retrieved April 20, 2022, from https://globalcompetitionreview.com/review/the-antitrust-review-of-the-americas/2022/article/united-states-pharmaceutical-antitrust.
• Impax Labs. v. FTC, 994 F.3d 484 (5th Cir. 2021)
• In re: Humira (Adalimumab) Antitrust Litig., 465 F. Supp. 3d 811 (N.D. Ill. June 8, 2020)
• In re: Sensipar (Cinacalcet Hydrochloride Tablets) Antitrust Litig., MDL No. 2895, 2020 WL 7022364 (D. Del. Nov. 30, 2020)
• Value Drug Co. v. Takeda Pharm., U.S.A., Civil Action 21-3500 (E.D. Pa. Dec. 28, 2021)